4 research outputs found
Poliserositis en el posparto. Presentación atípica de sarcoidosis
We report a case of a 37-year-old female patient admitted to our hospital for ascites and bilateral pleural effusion after a caesarean section. By thorough investigations and radiological examinations, she was eventually diagnosed as sarcoidosis. Treatment was started with a successful response.Mujer de 37 años que ingresa en nuestro servicio por ascitis y derrame pleural posteriores a la realización de una cesárea. Después del diagnóstico diferencial y las pruebas complementarias, se diagnostica de sarcoidosis. Se inicia tratamiento con evolución favorable
Síndrome de Marfan de presentación atípica, reflejo de una nueva mutación
Marfan syndrome (MS) is an inherited connective tissue disorder that affects the skeletal, cardiovascular, andmuscular systems of the eye. We present a MS case with an atypical presentation as acute lung edema thatreflects a new FBN1 mutation.El síndrome de Marfan (SM) es un desorden del tejido conectivo que afecta a los sistemas musculoesquelético, cardiovascular y ocular. Presentamos el caso de una paciente diagnosticada de SM tras sufrir un cuadro de edema pulmonar agudo, objetivándose a posteriori una nueva mutación del gen FBN1
Real-Life Impact of Glucocorticoid Treatment in COVID-19 Mortality: A Multicenter Retrospective Study
We aimed to determine the impact of steroid use in COVID-19 in-hospital mortality, in a retrospective cohort study of the SEMICOVID19 database of admitted patients with SARS-CoV-2 laboratory-confirmed pneumonia from 131 Spanish hospitals. Patients treated with corticosteroids were compared to patients not treated with corticosteroids; and adjusted using a propensity-score for steroid treatment. From March-July 2020, 5.262 (35.26%) were treated with corticosteroids and 9.659 (64.73%) were not. In-hospital mortality overall was 20.50%; it was higher in patients treated with corticosteroids than in controls (28.5% versus 16.2%, OR 2.068 [95% confidence interval; 1.908 to 2.242]; p = 0.0001); however, when adjusting by occurrence of ARDS, mortality was significantly lower in the steroid group (43.4% versus 57.6%; OR 0.564 [95% confidence interval; 0.503 to 0.633]; p = 0.0001). Moreover, the greater the respiratory failure, the greater the impact on mortality of the steroid treatment. When adjusting these results including the propensity score as a covariate, in-hospital mortality remained significantly lower in the steroid group (OR 0.774 [0.660 to 0.907], p = 0.002). Steroid treatment reduced mortality by 24% relative to no steroid treatment (RRR 0.24). These results support the use of glucocorticoids in COVID-19 in this subgroup of patients